Protection of endothelial cells by dextran sulfate in rats with thrombotic microangiopathy.
The characteristic features of thrombotic microangiopathy (TMA) include glomerular and peritubular capillary endothelial cell injury in association with loss of heparan sulfate proteoglycans on the cell surface and thrombus formation, followed by subsequent ischemic tubulointerstitial damage. It therefore was hypothesized that dextran sulfate (DXS) may protect the kidney against endothelial damage in a model of TMA. TMA was induced in rats by renal artery perfusion of an antiglomerular endothelial antibody, followed by the administration of DXS or vehicle. Renal damage was assessed by histologic analysis and measurements of blood urea nitrogen and creatinine. Whereas control rats developed severe renal failure with extensive glomerular and tubular injury, administration of DXS significantly protected renal function and preserved the glomerular endothelium and peritubular capillaries. The beneficial effect of DXS could be attributed to the ability of DXS to protect endothelial cells from coagulation and complement activation, as demonstrated by the histologic analysis. In addition, binding of the administered DXS to the surface of the glomerular endothelium was confirmed in TMA rats, suggesting that DXS acts as a "repair coat" of injured glomerular endothelium. In conclusion, DXS protects the kidney from experimental TMA. This protection may be mediated by DXS's binding directly to the surface of glomerular endothelium and amelioration of coagulation, complement activation, and cellular matrix loss.
Eto
Nobuaki
N
Division of Nephrology and Endocrinology, University of Tokyo, School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Kojima
Ichiro
I
Uesugi
Noriko
N
Inagi
Reiko
R
Miyata
Toshio
T
Fujita
Toshiro
T
Johnson
Richard J
RJ
Shankland
Stuart J
SJ
Nangaku
Masaomi
M
D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology* / Q000627:therapeutic use*; D016264:Dextran Sulfate / Q000494:pharmacology* / Q000627:therapeutic use*; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000187:drug effects*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
D000925:Anticoagulants; D016264:Dextran Sulfate